Pattern of plasma lipoprotein (a) in Sudanese patients with coronary

Similar documents
Comparison of Lipoprotein (a) and Apolipoproteins in Children with and without Familial History of Premature Coronary Artery Disease

Statistical Fact Sheet Populations

Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases

Atherosclerotic Disease Risk Score

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

CLINICAL OUTCOME Vs SURROGATE MARKER

1. Which one of the following patients does not need to be screened for hyperlipidemia:

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

CVD Prevention, Who to Consider

Association of Cardiovascular Risk Factors in Hypertensive Subjects with Metabolic Syndrome De ned by Three Different De nitions

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

Lipoprotein (a) and Apolipoprotein (a) Isoforms in Patients with Acute Myocardial Infarction

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

CONTRIBUTING FACTORS FOR STROKE:

Reeju Manandhar, Chaofeng Sun. Original article

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.

Lipoprotein (a): Is it important for Friedewald formula?

The Best Lipid Fraction for the Prediction of the Population at Risk of Atherothrombotic Disease. William E. Feeman, Jr., M.D.

Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients

Lipoprotein Subclassification Testing for Screening, Evaluation and Monitoring of Cardiovascular Disease

DONOR CORONARY ANGIOGRAPHY PROTOCOL

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Echocardiography analysis in renal transplant recipients

Life Science Journal 2018;15(12)

Association of Plasma Lipid profile and HbA1c among Saudi Patients with Coronary Heart Diseases, at King Abdulaziz Medical City, Riyadh

Assessment of vitamin D levels in patients with acute coronary syndrome

Acute Coronary Syndromes (ACS)

Lipid Panel Management Refresher Course for the Family Physician

Supplementary Online Content

Title for Paragraph Format Slide

FY 2011 WISEWOMAN Approved ICD-9 Code List

Using the New Hypertension Guidelines

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease


Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

MPS and Calcium Score in asymptomatic patient F. Mut, J. Vitola

Dr. Suzanne Steinbaum Director, Women and Heart Disease Lenox Hill Hospital New York

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures

COMPARISON OF LIPID PROFILE IN DIABETIC AND NON DIABETIC MALE AND FEMALE BELOW AND ABOVE THE 45 YEARS OF AGE GROUP

Periodontal disease is characterized by progressive periodontal pathogens. It is known that coronary heart disease is

Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?

Lipoprotein(a) associated with coronary artery disease in older women: age and gender analysis

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri

Wellness: Concepts and Applications 8 th Edition Anspaugh, Hamrick, Rosato

Journal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Association of Major Modifiable Risk Factors Among Patients with Coronary Artery Disease - A Retrospective Analysis

New Paradigms in Predicting CVD Risk

Smoking and Ischemic Stroke

YOUR INFORMATION. Ischemic Heart Disease

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease

Prevalence and Positive Predictive Value of Poor R-Wave Progression and Impact of the Cardiothoracic Ratio

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

CVD risk assessment using risk scores in primary and secondary prevention

Cardiovascular Disease Risk Factors:

Ischemic Heart Disease Mortality, Morbidity and Risk Factors of Coronary Care Unit Patients

CLINICAL COURSE, MANAGEMENT AND IN-HOSPITAL OUTCOMES

National public health campaigns have attempted

Supplementary Online Content

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

The Framingham Coronary Heart Disease Risk Score

Heart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing

the U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Prevalence of Cardiac Risk Factors among People Attending an Exhibition

Indian Journal of Basic & Applied Medical Research; December 2011: Issue-1, Vol.-1, P

Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease

How would you manage Ms. Gold

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.

Heart Disease in Women. Charlotte A. Lee, M.D., DBIM, FLMI

Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly

Preventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal

Comparison of Mean Platelet Volume in Acute Myocardial Infarction vs. Normal Coronary Angiography

Diabetes and the Heart


Life Science Journal 2016;13(5) Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

SUPPLEMENTAL MATERIAL

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Stroke is the third leading cause of death in the

Psychological Factors and Cardiac Risk and Impact of Exercise Training Programs A Review of Ochsner Studies

ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk

Lnformation Coverage Guidance

C-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS

Risk Factors for Ischemic Stroke: Electrocardiographic Findings

Transcription:

Pattern of plasma lipoprotein (a) in Sudanese patients with coronary artery disease Mansour Eltahir Farah 1, Khairia Eltahir Abdullah 2, Huda HM Elhassan 3, Mohammed O EH Gadour 1, Mohammed Saeed Alkhaleefa 1 Abstract: Coronary artery disease is one of the leading causes of death world wide. lipoprotein(a) [Lp (a)] is a cholesterol rich plasma lipoprotein. Its structure and composition closely resembles low density lipoproteins (LDL). Elevated Lp (a) is the most common familial lipoprotein disorder in patients with premature Coronary Artery Disease (CAD). Objective: To study the pattern of plasma LP(a) levels in Sudanese patients who presented with coronary artery disease [CAD]. Material and Methods: This is a case control study. 30 patients randomly selected from a pool of 624 patients admitted to the coronary care unit [C.C.U] in Elshaab Teaching Hospital with acute coronary syndrome in the period from April 2004 to July 2005 while 30 patients with non ischaemic cardiac problems admittedd to the same hospital were randomly selected as a matched control group. Serum LP(a), cholesterol and low-density lipoprotein cholesterol (LDL- C) concentrations were determined using the conventional enzymatic colorimetric methods. Results: LP(a), cholesterol and LDL levels were all significantly high in patients with CAD [P <0.005, 0.003 and 0.001 respectively]. Lp(a) is also high in patients blew 60years of age. High LP(a) correlates with high cholesterol, LDL and other risk factors. The role of Lp(a) as an independent risk factor is less well established as 3 (20%) patients only of the 15 patients with no other risk factors had high LP(a) level. Conclusion: This study demonstrated significant Lp(a) level in patients with other risk factors of CAD [including cholesterol and LDL]. Key words: Lipoprotein A, Coronary artery disease Introduction Coronary artery disease [CAD] is one the leading causes of death for both men and women world wide 1. CAD risk increases with age, obesity and certain diseases such as diabetes, hypertension, high serum cholesterol level, high level of low-density lipoprotein (LDL) in the blood and with certain social habits such as smoking 2. Inherited factors may also increase the likelihood of developing CAD 3. Lipoprotein a [Lp (a)] is a cholesterol rich plasma lipoprotein which was first identified as plasma antigen in 1963 by Berg 4. Its structure and composition closely resemble low density lipoproteins (LDL). The plasma concentration of Lp (a) is mostly genetically determined 5. Elevated Lp (a) is the most common familial lipoprotein disorder in patients with premature CAD 6. High levels of Lp(a) are associated with significantly increased risk in subjects under 60 years but may be of less significance in the elderly patients 7. Lp (a) level increases with age and in patients with renal insufficiency, nephritic syndrome and kidney transplantation 8. However, in a brief study done in Sudan, the levels of lipoproteins were found to be relatively low/normal in patients with chronic renal diseases and that was attributed to diet and possibly genetic factors 9 1Department. of Medicine. Omdurman Islamic University. 2. Department of biochemistry. Omdurman Islamic University 3.ElShaab Hospital. This study had determined the pattern of plasma Lp(a) in Sudanese patients who presented with coronary artery disease CAD Material and methods This is a case control study. The study group [group I] includedd 30 patients randomly selected from a pool of 624 patients admitted to the coronary care unit [C.C.U] in Elshaab Teaching Hospital with acute coronary syndrome in the period April 2004 to July 2005 while 30 patients with non ischaemic cardiac problems admitted to the same hospital were randomly selected as a matched control group [group II]. All patients provided a complete medical history, had through clinical examination and routine laboratory investigations. Serum Lp(a), cholesterol and low density lipoprotein cholesterol (LDL-C) concentrations were determined using the conventional enzymatic colorimetric methods. The cut off figures for elevated markers were taken as follows: - >30 mg for Lp(a). - >240 mg for Cholestrol. - >160 mg for LDL. Results were analyzed using Statistical Package for Social Sciences (SPSS) personal computer programme. Results The age in group I ranged between 40 and 80 years while that of group II was between 41 and 78 yreas. Men represented 76% and 67% in 197

Pattern of plasma lipoprotein (a), Mansour EF et al the two groups respectively. There were no significant differences in the mean age values or sex distribution between the two groups [Table I]. Table I : Age and sex Distribution of the study groups: The most prevalent risk factors were hypertension and diabetes while smoking is the least frequent one [Table 6]. Table4: The percentage of the significant LP(a) level among the different variables Age in years <60 >60 Study group Male Female 9 1 14 6 Control group Male Female 8 2 12 8 Percentage total High Variable level 39% 23 9 Male 71% 7 5 Female 70% 10 7 60years< 35% 20 7 >60years 73% 15 11 Risk factor 20% 15 3 No Risk factor Total 23 7 20 10 Table 5: The correlation between significant LP(a) levels and the different variables. Group I showed significantly higher levels of the three biochemical markers (Lp (a), cholesterol and LDL) than group II (Table 2). Table 2:The Biochemical Data In The Studied Group. High level of Study group Control group P value S. Lp(a) 14 3 0.005 S. cholestrol 8 1 0.003 S. LDL 7 1 0.001 Lp (a) was found to be more prevalent in patients with CAD than cholesterol and LDL [47% and 27% respectively], however there was a strong correlation between the high level of the three markers as 75% of the patients with high cholesterol and LDL has also high level of Lp(a) (Tables 2 and 3). Table 3: The correlation between LP(a) and Cholestrol level High Normal LP(a) LP(a) High Cholestrol Normal Cholestrol 6 8 2 14 There was high prevalence of elevated Lp(a) levels in female gender (71%). It is also high in patients blew 60 years of age (70%) and in those with more than one risk factor (73%) [Tables 4 and 5]. 198 P LP (a) <30 LP (a) >30 Variable value 14 9 Male 0.005 2 5 Female 3 7 60years< 0.003 13 7 >60years 4 11 Risk factor 0.002 12 3 No Risk factor Table 6:: Number of patients in group 1 with traditional risk factors. Number of Traditional Risk Factors. patients 7 Diabetes mellitus 8 Hypertension 2 Smoking Discussion Lp (a) level is genetically determined. The normal range of Lp (a) in human varies in different ethnic groups. The normal range in Caucasians is similar to that in Asians. However people of African descent have demonstrated normal range that are twice higher than Caucasians. Native American and Mexican populations have normal ranges that are half of the Caucasians populations 10. This study demonstrated significant high levels of Lp(a) in Sudanese patients with CAD and showed positive correlation between Lp(a) and the other risk factors (including high levels of Cholestrol and LDL) which is in keeping with the multi factorial etiology of CAD 11 70% of our patients who were <60years of age in the study group showed significant high levels of Lp(a). This fining may be consistent with the results of Kostner and other workers who reported that Lp(a) may be an important initiator

Pattern of plasma lipoprotein (a), Mansour EF et al and promoter, as well as an early marker for the premature CAD 11,12. Significantly high levels of Lp(a) were seen in 5[71%] of the females compared to 9[39%] of males. Our study demonstrated that 20% of the patients with CAD, who had no other risk factors had significantly high Lp(a) levels (table 4). It also showed that the prevalence of high Lp(a) in group I is more than that of cholesterol and LDL (table3). These findings may suggest a role for Lp(a) as an independent risk factor which keeps with the work of Sandkamp 12. The same result was observed in the Framingham Offspring Study 7 However, these results contrast, the Physicians Health Study and Quebec Cardiovascular Study 13,14. These differences in reports could be attributed to differences in sample collection, storage and type of Lp(a) assays. A recent metaanalysis 15, including 27 published prospective studies (18 population- based and 9 with pre existing CAD) and involving 5436 cases with mean follow up of 10 years, demonstrated a moderate and independent association of Lp(a) and CAD. Conclusion This study suggests that Lp (a) level is significantly high in patients with CAD and those blew 60years of age. It is associated with other risk factors and correlates with Cholestrol and LDL levels. The sample size is rather small to suggest that it is an independent risk factor (although it was significantly high in 20% of the patients who had no other risk factor). Further studies are needed to address the significance of Lp(a) in patients with CAD blew 60 years of age who has no other risk factors. References 1. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis ans survival. Am J Cardiol 1972;29:154-163. 2. Cheitlin MD, Sokolow M, McIlory MB. Coronary heart disease. In:Clinical cardiology (6 th edn). London :Lange Medical Publication,1993:147. 3. Berg K. A new serum type system in the man: The Lp system. Acta Pathol Microbiol Scand 1963;59:362-82. 4. Angles-Cano; Structural basis for the pathophysiology of lipoprotein (a) in the atherothrombotic process. Braz J Med Biol Res 1997 Nov;30(11):1271-80. 5. Genest JJ Jr, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease.circulation 1992;85:2025-33. 6. Klausen, I C, Sjol, Hansen P S, Gerdes, L U et al. Faergeman, o;atherosclerosis. 1997 Jul 11;132 (1):77-84; 7. Bostom AG, Cupples LA, Jenner JL et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. Aprospective study. Jama 1996;276:544-8. 8. Monica Acevado, Tagle R, Simpfendorfer C. Nontraditional risk factors for Atherosclerosis,Revista Medica De Chile (2001);129:1-14. 9. Fathia H Mubarak, Balila MH and Mohammed BA. Lipoprotein paatern in patients with chronic renal failure and those who had renal transplanatation. Sudan JMS 2006; 1(1):37-40. 10. Kark JD, Sandholzer C. Atherosclerosis 98:1993:139-151. 11. Kostner, G.M., P.Avogaro &G.Cazzolato. Lipoprotein (a) and the risk for myocardial infarction. Atherosclerosis 198; 138:51-61. 12. Sandkamp M. Lipoprotein (a) is an independanet risk factor for myocardial infraction at a younger age. Clin Chem 1990; 36:20-23. 13. Ridker PM, Hennekens CH, Stamper MJ. A prospective study of lipoprotein (a) and the risk of myocardial infraction. JAMA 1993;270:2195-9. 14. Cantin B, Gagon F, Moorjani S et al. Is lipoprotein (a) an independent risk factor for ischemic heart in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-25. 15. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1028-5. 199

200

201